Sarepta Therapeutics’ (SRPT) “Buy” Rating Reiterated at Needham & Company LLC

Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “buy” rating reaffirmed by research analysts at Needham & Company LLC in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $202.00 price target on the biotechnology company’s stock. Needham & Company LLC’s price objective would suggest a potential upside of 71.90% from the company’s current price.

Other analysts have also recently issued research reports about the stock. Robert W. Baird cut their target price on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a research note on Thursday, November 7th. Cantor Fitzgerald upgraded Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $152.00 to $167.00 in a research note on Thursday, November 7th. Raymond James restated an “outperform” rating and issued a $150.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, October 10th. Evercore ISI lowered their price target on Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating on the stock in a research note on Thursday, November 7th. Finally, Guggenheim increased their price objective on Sarepta Therapeutics from $148.00 to $150.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Sarepta Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $178.71.

Sarepta Therapeutics Trading Up 0.5 %

Shares of NASDAQ:SRPT opened at $117.51 on Monday. The business’s 50 day moving average price is $122.63 and its 200-day moving average price is $127.67. Sarepta Therapeutics has a 1 year low of $102.15 and a 1 year high of $173.25. The firm has a market capitalization of $11.22 billion, a price-to-earnings ratio of 94.01 and a beta of 0.77. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03.

Insider Buying and Selling at Sarepta Therapeutics

In other news, Director Kathryn Jean Boor sold 1,636 shares of the business’s stock in a transaction that occurred on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total value of $205,399.80. Following the sale, the director now directly owns 5,880 shares of the company’s stock, valued at approximately $738,234. The trade was a 21.77 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the transaction, the director now directly owns 22,840 shares of the company’s stock, valued at $2,851,345.60. The trade was a 31.49 % decrease in their position. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by corporate insiders.

Institutional Trading of Sarepta Therapeutics

Several hedge funds have recently modified their holdings of SRPT. Wellington Management Group LLP grew its stake in Sarepta Therapeutics by 32.3% during the 3rd quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company’s stock worth $340,527,000 after purchasing an additional 665,087 shares in the last quarter. Erste Asset Management GmbH purchased a new stake in shares of Sarepta Therapeutics during the third quarter worth approximately $79,425,000. Janus Henderson Group PLC raised its holdings in Sarepta Therapeutics by 14.2% in the third quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company’s stock valued at $544,408,000 after acquiring an additional 543,143 shares in the last quarter. Soros Fund Management LLC purchased a new position in Sarepta Therapeutics in the third quarter worth approximately $25,800,000. Finally, Swedbank AB acquired a new position in Sarepta Therapeutics during the 4th quarter worth approximately $16,706,000. 86.68% of the stock is currently owned by institutional investors and hedge funds.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.